- AminosalicylatesCorticosteroids for IBDCytokine-Targeted Therapies for IBDJanus Kinase Inhibitors for IBDDrugs Targeting Leukocyte Trafficking for IBDPPAR-γ Ligands for IBDAgents Targeting the TGF-β/Smad System in IBDMatrix Metalloproteinase Inhibitors for IBDImmunotherapies for IBDDrugs Targeting Toll-like Receptors in IBDS1P Receptor Modulators for IBD
- Antibiotic Therapies for IBDProbiotic Therapies for IBDFecal Microbiota Transplantation for IBDCell-based Therapies for IBD
- Drug Target Discovery for IBDLead Discovery for IBDLead Optimization for IBD
- In Vitro ADMEIn Vivo ADME TestingPharmacokinetic EvaluationBioanalysisMetabolite Profiling and IdentificationPreclinical Toxicology Studies for IBD DrugsIn Vitro Efficacy Testing for IBD Drugs
- Disease Activity Index AssessmentColon Length and Weight AssessmentColonoscopyHistology and Immunohistochemistry EvaluationInflammatory Marker AssessmentOxidative Stress Marker AssessmentIntestinal Permeability MeasurementImaging Services
- IBD Immunopathogenesis AnalysisGut Microbiota AnalysisGenetic Studies of IBDIntestinal Barrier Dysfunction in IBD
- Serum Biomarker Discovery for IBDSerological Biomarker Discovery for IBDInquiry
Development of Fecal Microbiota Transplantation for IBD
Fecal microbiota transplantation (FMT) involves the infusion of a fecal suspension prepared from a healthy donor into the patient's gut to restore the healthy composition and function of the microbiota. FMT has been successfully used to treat recurrent Clostridium difficile infection, leading to investigations into its application in inflammatory bowel disease (IBD). Most current therapeutic strategies are associated with high costs and many adverse effects by directly targeting the immune response, so modifying the microbial environment by FMT offers an alternative approach that could indirectly influence the immune system of host in a safe way.
Fig. 1. How FMT treats dysbiosis: dysbiosis is characterized by an increase in pro-inflammatory bacteria and a decrease in anti-inflammatory ones. (Fanizzi, et al., 2024)
Our Fecal Microbiota Transplantation Development Services
At Ace Therapeutics, we are highly committed to providing FMT development services. Our team has the ability to study the beneficial effects of FMT in animal models of IBD and also figure out the gut microbiota and intestinal mucosal immune signaling pathway that goes with it. Our services bring a broad knowledge of the FMT mechanism to light which is guiding our clients to be able to explain better and make use of its therapeutic potential.
We can carry out a series of experiments to identify the microbes that are responsible for the therapeutic effect of FMT and to develop more effective microbiota-based therapeutics for IBD.
FMT Preparation
- Healthy donor fecal bacteria suspension is obtained from universal stool banks. The donor material is identified, rigorously screened and pre-stored for high microbiota richness and abundance of beneficial strains. Our team of experts is available to provide guidance throughout the donor and recipient selection process.
- FMT delivery varies according to specific protocols, including upper endoscopy, nasoenteric tubes or capsules for upper gastrointestinal (GI) tract administration, colonoscopy, flexible sigmoidoscopy, or enemas for lower GI tract administration.
Preclinical Evaluation of FMT in IBD
We can transmit microbiome samples from a healthy donor to germ-free mice or to the wild type of mice, followed by the induction of colitis using the DSS treatment, and finally conduct multiple experiments to determine if gut microbiota are the players in microbiota-based interference of colitis via FMT.
- Evaluation of the effects of FMT on clinical symptoms of DSS-induced colitis, including weight loss, stool characterization, and fecal bleeding.
- We test the colonic inflammatory markers, Myeloperoxidase (MPO) and Eosinophil peroxidase (EPO) by ELISA, to study the effect of the FMT.
- We analyze the effect of the effects of HD and UC intervention on the balance of cytokines that regulate the immune response in treated mice by the ELISA of colon and (or) serum samples containing pro-inflammatory factors and anti-inflammatory factors.
- We take the detection of the mucosal tight junction proteins in mouse intestinal samples and the determination of the serum levels of proteins related to intestinal permeability into our evaluation as an effect of FMT in mice that have DSS-induced colitis.
- We analyze the intestinal microbial composition and metabolism by metagenomic analysis, aiming to help clients discover targets for IBD treatment from the perspective of intestinal microecology.
- Mouse gut microbiome communities by the method of macro-genomics are studied.
- RNA sequencing and GO enrichment analysis are performed in tissue samples with colon origin to decipher the differentially expressed genes, thereby investigating the molecular targets that influence the effect of FMT.
Ace Therapeutics helps clients to explore the mechanism of FMT in the treatment of experimental colitis by analyzing the gut microbiota and colonic transcriptome. Our team is committed to supplying targets and insights for IBD treatment from an approach of intestinal microecology. If you are interested in our services, please click this link to contact us and get more information about us.
Reference
- Fanizzi, F., et al. (2024). The Role of Fecal Microbiota Transplantation in IBD. Microorganisms, 12(9), 1755.
! For research use only, not intended for any clinical use.Related Services
Copyright © Ace Therapeutics. All rights reserved.
Customized Services